




Searching News Database: UCB
HSMN NewsFeed - 11 Aug 2020
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
HSMN NewsFeed - 13 Jun 2018
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
HSMN NewsFeed - 23 Oct 2017
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
HSMN NewsFeed - 22 Jul 2016
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
HSMN NewsFeed - 27 Nov 2015
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
HSMN NewsFeed - 9 Jun 2015
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
HSMN NewsFeed - 19 Aug 2014
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
HSMN NewsFeed - 6 Aug 2014
Nodality Expands Senior Leadership Team, Appoints Kathleen LaPorte as Chief Business Officer
Nodality Expands Senior Leadership Team, Appoints Kathleen LaPorte as Chief Business Officer
HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
HSMN NewsFeed - 14 Jan 2014
Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer
Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 10 May 2012
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer
HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 5 Aug 2010
Cornerstone Therapeutics Announces Development of Generic for Tussionex(R)
Cornerstone Therapeutics Announces Development of Generic for Tussionex(R)
HSMN NewsFeed - 3 May 2010
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 23 Apr 2010
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
HSMN NewsFeed - 10 Nov 2009
Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
HSMN NewsFeed - 5 Feb 2009
Dr. Reddy's Announces Five ANDA Approvals and Generic Product Launches in the US Market
Dr. Reddy's Announces Five ANDA Approvals and Generic Product Launches in the US Market
HSMN NewsFeed - 9 Jan 2009
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
HSMN NewsFeed - 25 Sep 2008
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
HSMN NewsFeed - 8 Sep 2008
Perrigo Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon
Perrigo Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon
HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
HSMN NewsFeed - 8 May 2008
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
HSMN NewsFeed - 20 Mar 2008
CHMP Upholds Negative Opinion for the EU Application for Cimzia(R) in the Treatment of Crohn's Disease
CHMP Upholds Negative Opinion for the EU Application for Cimzia(R) in the Treatment of Crohn's Disease
HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
HSMN NewsFeed - 20 Mar 2008
UCB advises US-physicians to down-titrate patients on Neupro(R) in view of out-of-stock situation in the US
UCB advises US-physicians to down-titrate patients on Neupro(R) in view of out-of-stock situation in the US
HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 16 Jan 2008
Teva Specialty Pharmaceuticals and UCB Announce U.S. Respiratory Collaboration Agreement
Teva Specialty Pharmaceuticals and UCB Announce U.S. Respiratory Collaboration Agreement
HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
HSMN NewsFeed - 11 Dec 2007
New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
HSMN NewsFeed - 16 Nov 2007
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn's Disease
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn's Disease
HSMN NewsFeed - 20 Aug 2007
Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
HSMN NewsFeed - 17 Aug 2007
UCB Announces Submission of Lacosamide Marketing Application for Diabetic Neuropathic Pain
UCB Announces Submission of Lacosamide Marketing Application for Diabetic Neuropathic Pain
HSMN NewsFeed - 31 Jul 2007
Neuren to Obtain Late Stage Compound Through Hamilton Pharmaceuticals Acquisition
Neuren to Obtain Late Stage Compound Through Hamilton Pharmaceuticals Acquisition
HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 26 Jun 2007
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
HSMN NewsFeed - 13 Jun 2007
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
HSMN NewsFeed - 20 Mar 2007
Keppra(R) Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types
Keppra(R) Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types
HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
HSMN NewsFeed - 25 Sep 2006
sanofi-aventis and UCB Sign a Co-Promotion Agreement for Xyzal(R) in the United States
sanofi-aventis and UCB Sign a Co-Promotion Agreement for Xyzal(R) in the United States
HSMN NewsFeed - 25 Sep 2006
UCB and sanofi-aventis sign a co-promotion agreement for Xyzal(R) in the United States
UCB and sanofi-aventis sign a co-promotion agreement for Xyzal(R) in the United States
HSMN NewsFeed - 21 Aug 2006
Verus Pharmaceuticals Announces Agreement with UCB for Commercialization of Twinject(R) in Europe
Verus Pharmaceuticals Announces Agreement with UCB for Commercialization of Twinject(R) in Europe
HSMN NewsFeed - 14 Aug 2006
Osiris Announces Expansion of Board of Directors and Key Additions to its Senior Management Team
Osiris Announces Expansion of Board of Directors and Key Additions to its Senior Management Team
HSMN NewsFeed - 1 Aug 2006
FDA Approves ADEPT(R) Adhesion Reduction Solution [4% Icodextrin Solution]
FDA Approves ADEPT(R) Adhesion Reduction Solution [4% Icodextrin Solution]
HSMN NewsFeed - 6 Jul 2006
AtheroGenics Announces Promotion of Joseph M. Gaynor, Jr. to Senior Vice President
AtheroGenics Announces Promotion of Joseph M. Gaynor, Jr. to Senior Vice President
HSMN NewsFeed - 25 May 2006
UCB Sells to Adams Respiratory Therapeutics OTC Delsym(R) 12-Hour Cough Suppressant Liquids
UCB Sells to Adams Respiratory Therapeutics OTC Delsym(R) 12-Hour Cough Suppressant Liquids
HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
HSMN NewsFeed - 28 Apr 2006
UCB Submits Marketing Authorisation Application in Europe for CIMZIATM, a New Crohn's Disease Therapy
UCB Submits Marketing Authorisation Application in Europe for CIMZIATM, a New Crohn's Disease Therapy
HSMN NewsFeed - 7 Mar 2006
Schering-Plough Intensifies Focus On Europe, Latin America And Asia-Pacific
Schering-Plough Intensifies Focus On Europe, Latin America And Asia-Pacific
HSMN NewsFeed - 2 Mar 2006
UCB Submits Biologics License Application to FDA for New Treatment in Crohn's Disease
UCB Submits Biologics License Application to FDA for New Treatment in Crohn's Disease
Additional items found! 37

Members Archive contains
37 additional stories matching:
UCB
(Password required)
UCB
(Password required)